KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

AbCellera Biologics (ABCL) EPS (Weighted Average and Diluted) (2020 - 2023)

AbCellera Biologics' EPS (Weighted Average and Diluted) history spans 4 years, with the latest figure at -$0.17 for Q4 2023.

  • For the quarter ending Q4 2023, EPS (Weighted Average and Diluted) fell 70.0% year-over-year to -$0.17, compared with a TTM value of -$0.52 through Dec 2023, down 204.0%, and an annual FY2024 reading of -$0.55, down 7.84% over the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2023 was -$0.17 at AbCellera Biologics, down from -$0.1 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $0.54 in Q1 2022, with the low at -$0.17 in Q4 2023.
  • Average EPS (Weighted Average and Diluted) over 4 years is $0.06, with a median of -$0.02 recorded in 2020.
  • Year-over-year, EPS (Weighted Average and Diluted) soared 3800.0% in 2021 and then plummeted 450.0% in 2023.
  • Tracing ABCL's EPS (Weighted Average and Diluted) over 4 years: stood at $0.44 in 2020, then plummeted by 56.82% to $0.19 in 2021, then crashed by 152.63% to -$0.1 in 2022, then crashed by 70.0% to -$0.17 in 2023.
  • Per Business Quant, the three most recent readings for ABCL's EPS (Weighted Average and Diluted) are -$0.17 (Q4 2023), -$0.1 (Q3 2023), and -$0.11 (Q2 2023).